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ABSTRACT
Objective: Evaluate the effects of a novel autonomic regulation therapy (ART) via vagus nerve stimula-
tion (VNS) in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction during
a 12-month follow-up period.
Methods: The Autonomic Regulation Therapy for the Improvement of Left Ventricular Function and Heart
Failure Symptoms (ANTHEM-HF) study enrolled 60 subjects with New York Heart Association class II-
III HF and low left ventricular ejection fraction (≤40%), who received open-loop ART using VNS randomized
to left or right cervical vagus nerve placement and followed for 6 months after titration to a therapeutic
output current (2.0 ± 0.6 mA). Patients received chronic stimulation at a frequency of 10 Hz and pulse du-
ration of 250 μsec. Forty-nine subjects consented to participate in an extended follow-up study for an additional
6 months (12 months total posttitration) to determine whether the effects of therapy were maintained.
Results: During the 6-month extended follow-up period, there were no device malfunctions or device-
related serious adverse effects. There were 7 serious adverse effects unrelated to the device, including 3
deaths (2 sudden cardiac deaths, 1 worsening HF death). There were 5 nonserious adverse events that were
adjudicated to be device-related. Safety and tolerability were similar, and there were no significant differ-
ences in efficacy between left- and right-sided ART. Overall, mean efficacy measure values at 12 months
were not significantly different from mean values at 6 months.
Conclusions: Chronic open-loop ART via left- or right-sided VNS continued to be feasible and well-
tolerated in patients with HF with reduced EF. Improvements in cardiac function and HF symptoms seen
after 6 months of ART were maintained at 12 months. (J Cardiac Fail 2016;22:639–642)
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Chronic heart failure (HF) is characterized by autonomic dys-
function, including excessive sympathetic activation and
concomitant parasympathetic withdrawal.1,2 This autonomic im-
balance is associated with cardiovascular dysregulation,
worsening HF, and increased risk of mortality independent of
ejection fraction (EF) and ventricular arrhythmias.3–5 The Au-
tonomic Regulation Therapy for the Improvement of Left
Ventricular Function and Heart Failure Symptoms (ANTHEM-
HF) Study, a multicenter, open-label feasibility study, was the
first ever to compare the effects of open-loop autonomic reg-
ulation therapy (ART) using right- and left-sided vagus nerve
stimulation (VNS), and demonstrated the potential safety, tol-
erability, and efficacy of ART in patients with chronic, stable,
symptomatic HF with reduced EF (HFrEF).6 The Extension
Study of Neural Regulation therapy on Myocardial Function
in Heart Failure (ENCORE) study enrolled ANTHEM-HF
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patients for an additional 6 months to determine whether the
safety and beneficial effects of chronic ART therapy are
maintained.
Methods
Study Design
The study design has been previously published.7 Briefly,
the ANTHEM-HF study enrolled 60 subjects in New York
Heart Association (NYHA) class II-III HF with left ventricu-
lar EF (LVEF) ≤40%. Subjects received VNS Therapy System
implantation (Demipulse Model 103 pulse generator and
PerenniaFLEX Model 304 lead, Cyberonics, Houston, TX)
with lead placement randomized 1:1 to either the right or left
cervical vagus nerve. Stimulation parameters were system-
atically adjusted over a 10-week titration period to a pulse
width of 250 μsec and a pulse frequency of 10 Hz in all pa-
tients. The mean output current at the end of titration was
2.0 ± 0.6 mA; this stimulation was maintained throughout the
extension period. At the end of the 6-month follow-up period,
49 patients (23 left-sided, 26 right-sided) consented to par-
ticipate in a 6-month extended follow-up study, with follow-
up visits at 9 and 12 months posttitration.
All outcomes measurements were made at the end of the
extension period (12 months after VNS titration in the
ANTHEM-HF study) and were compared with 6-month mea-
surements and secondarily to baseline measurements.
Endpoints
The primary safety endpoint was the incidence of proce-
dure and device-related adverse events. The primary efficacy
endpoints were changes in LVEF and left ventricular end sys-
tolic volume (LVESV). Secondary endpoints included left
ventricular end-systolic diameter (LVESD); NYHA function-
al class; 6-minute walk test; Minnesota Living with Heart Failure
Questionnaire; mean heart rate and heart rate variability;
N-terminal pro-BNP and high-specificity C-reactive protein.
Data Analysis
All transthoracic echo recordings and blood samples were
deidentified of patient and sample source before being sent
to core laboratories for interpretation by blinded experts. An
independent Data Safety and Monitoring Committee oversaw
the study, and all adverse events were adjudicated by an in-
dependent Clinical Events Adjudication Committee.
Safety measures were summarized and described. Distri-
butions of continuous measures and changes are expressed
as mean and standard deviation or median (interquartiles) when
skewed. Generalized linear models with an identity link and
exchangeable correlation matrix were used to test for statis-
tically significant changes in continuous measures of efficacy
between month 6 and month 12. Secondarily, 12-month mea-
sures were compared to baseline. Population-averaged
estimates are reported. Tests of interactions between side of
VNS and follow-up month were done to test for differences
before pooling the results from both sides of VNS. Biomarker
values were log-transformed to normalize their distributions.
Results
Baseline Characteristics of Patients
Baseline characteristics of the 49 patients who consented
to extended follow-up are summarized in Table 1 and com-
pared with all 60 ANTHEM-HF patients. There were no
remarkable differences. Of the 57 patients who were poten-
tially eligible for inclusion in the extension study, 49 (85%)
gave informed consent to participate, 5 (8%) declined for
unknown reasons, and 3 (5%) did not respond to invitations
to participate. At baseline (ANTHEM-HF enrollment), ex-
tended follow-up patients were either NYHA class II (57%)
or class III (43%), with an average LVEF of 34 ± 8%. The
average LVESD and LVEDD were 50.0 ± 7.6 mm and
60.6 ± 6.4 mm, respectively. Patients received optimum phar-
macological therapy for HF, with 100% receiving β-blocker
therapy and 84% receiving angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker therapy. There were
no significant changes in HF medications or VNS param-
eters during the extended follow-up study.
Safety Assessment
Table 2 summarizes the adverse events in the 6- to 12-
month extension period. All serious adverse events (SAEs)
Table 1. Baseline Characteristics of Enrolled Patients
ANTHEM-HF
(n = 60)
ANTHEM-HF
Extension
(n = 49)
Demographics
Age (y) 52 ± 12 52 ± 13
Male (%) 87 86
HF etiology (%)
Ischemic 75 84
Nonischemic 25 16
Clinical examination
NYHA class II/III 34/26 28/21
Body mass index (kg/m2) 24.1 ± 4.1 24.4 ± 4.4
LVEF (%) 32.4 ± 7.2 33.0 ± 7.3
LVESV (mL) 107.9 ± 40.1 102.0 ± 36.9
LVESD (mm) 51.6 ± 7.9 50.0 ± 7.6
LVEDD (mm) 61.7 ± 6.7 60.6 ± 6.4
HR (bpm) 78 ± 10 76 ± 10
Systolic blood pressure (mmHg) 113 ± 15 111 ± 13
Diastolic blood pressure (mmHg) 73 ± 9 71 ± 8
HF drug treatment (%)
β-blocker 100 100
ACE-I or ARB 85 84
Aldosterone antagonist 75 76
Digoxin 32 29
Loop diuretics 88 86
ICD implantation 0 0
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin re-
ceptor blocker; eGFR, estimated glomerular filtration rate; HF, heart failure;
HR, heart rate; ICD, implantable cardioverter defibrillator; LVEDD, left ven-
tricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD,
left ventricular end systolic diameter; LVESV, left ventricular end systolic
volume; NT-proBNP, N-terminal prohormone of brain natriuretic peptide;
NYHA, New York Heart Association.
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were formally adjudicated; there were no device-related SAEs.
There were 7 SAEs unrelated to the device, including 3 deaths
(2 sudden cardiac deaths, 1 worsening HF). There were 5
device-related nonserious adverse events (AEs) that were ad-
judicated to be device-related: 1 AE in the group receiving
left VNS and 4 in the group receiving right VNS. The non-
SAEs were mild dysphonia (3), implant site pain (1), and
shoulder pain (1). All nonserious device-related AEs re-
solved without sequelae. There were no device-related
infections or malfunctions, no unexpected device-related
adverse events, and no patients or physicians requested dis-
continuation of ART during the study.
Efficacy Assessments
Changes in efficacy endpoint measures are shown in Table 3.
With the exception of LVESV, all echocardiographic and HF
symptom measures were significantly improved at both 6 and
12 months compared with baseline; LVESV significantly im-
proved at 12 months, but not at 6 months, although there was
a consistent trend at 6 months. For all measures, improve-
ments in efficacy measures at 12 months were not significantly
greater than at 6 months. There were no significant dif-
ferences between left- and right-sided ART. A secondary
analysis showed that, compared with baseline values, all
echocardiographic measures significantly improved at 12
months in the pooled sample.
Discussion
This extension study has demonstrated that ART, using
open-loop natural frequency VNS, continues to be feasible
and well-tolerated at 12 months. No device-related SAEs were
observed during the 6-month extension, and only 5 device-
related non-SAEs were reported. The AE incidence was lower
than the incidence observed during the previous 6 months (12
AEs). In these few cases, stimulation parameters were ad-
justed to avoid side effects.
The primary finding of this study is that improvements in
efficacy observed after the first 6 months in ANTHEM-HF
were durable and maintained with an additional 6 months of
continued ART. Twelve-month improvements with chronic
open-loop ART were consistent with previously reported 12-
month improvements with chronic closed-loopART in a similar
HF population.8 However, the reason for the lack of further
improvement in efficacy parameters is unclear. The benefits
of ART derive from its antiadrenergic, antiarrhythmic, anti-
inflammatory, and antiapoptotic effects3; it is likely that ART
is providing a remodeling benefit through these mecha-
nisms, but is unable to completely resolve the underlying cardiac
damage. Further studies are required to confirm this hypothesis.
For the extension study cohort, there were significant im-
provements in all echocardiographic parameters (LVEF,
LVESV, and LVESD) after 12 months of ART. All subjec-
tive efficacy measures, including NYHA class, 6-minute walk
distance, and Minnesota Living with Heart Failure Question-
naire scores, showed a statistically significant improvement.
There was also improvement in heart rate variability. The blood
biomarkers high-specificity C-reactive protein and N-terminal
prohormone of brain natriuretic peptide did not change sig-
nificantly; however, this was a small study population, and
variability in the measurements may have been too great to
detect a change.
Table 2. Adverse Events During 6–12 Month Extension Period
Left Right Overall
Related SAEs 0 0 0
Unrelated SAEs 4 3 7
Death (sudden death) 1 1 2
Death (heart failure) 1 0 1
HF hospitalization 0 1 1
Ischemic stroke 1 0 1
Ventricular tachycardia 1 0 1
Cataract 0 1 1
Other related AEs 1 4 5
Dysphonia 1 2 3
Implant site pain 0 1 1
Shoulder pain 0 1 1
Device malfunctions 0 0 0
AE, adverse event; SAE, serious adverse event; other abbreviation as in
Table 1.
Table 3. Efficacy Measures*
Baseline 6 Mo
P Value
0–6 Mo 12 Mo
P Value
6–12 Mo
P Value
0–12 Mo
LVEF (%) 33.2 ± 7.4 38.5 ± 10.2 .0001 39.5 ± 10.4 NS <.0005
LVESV (mL) 102.0 ± 37.6 96.9 ± 44.3 NS 91.6 ± 43.5 NS .001
LVESD (mm) 50 ± 8 48 ± 8 <.0025 48 ± 8 NS .003
NYHA class (I/II/III/IV) 0/26/20/0 26/21/2/0 <.0001 32/14/0/0 NS <.0005
6MWT (m) 288 ± 64 348 ± 77 <.0001 352 ± 62 NS <.0005
MLHFQ score 39 ± 12 20 ± 9 <.0001 18 ± 9 NS <.0005
24-hr HR (beats/min) 78 ± 12 72 ± 10 <.005 70 ± 10 NS <.0005
SDNN (ms) 95 ± 29 106 ± 43 <.01 109 ± 40 NS <.01
NTproBNP, IQR (pg/mL) 6640 (267; 1748) 715 (344; 1239) NS 887 (359; 1691) NS NS
CRP, IQR (pg/dL) 1.5 (0.8; 4.0) 1.1 (0.5; 2.4) <.025 1.2 (0.6; 3.1) NS NS
*n = 46, excluding 3 patients who died before month 12.
6MWT, 6-minute walk test; CRP, C-reactive protein; HR, heart rate; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-proBNP, N-terminal
prohormone of brain natriuretic peptide; SDNN, standard deviation of normal to normal intervals; other abbreviations as in Table 1.
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Limitations
As with other early-stage studies of ART, the ANTHEM-
HF and extension studies were open-label and unblinded to
subjects and investigators, although the echocardiographic and
blood samples were analyzed in a blinded core laboratory.
It is possible that at least some of the subjective clinical im-
provements may have been influenced by placebo effects or
bias. However, given that the placebo effect is known to de-
crease over time, the preservation of the cardiovascular
improvements observed after 12 months of follow-up would
argue against a major role of these effects.8 Also, because the
study was conducted in India, it is possible to question whether
ethnicity or local standards of practice may have affected the
results; however, it is noteworthy that ANTHEM-HF and this
extension study were conducted with adjuvant pharmaceu-
tical management meeting Western standards, in patients with
HFrEF with baseline demographics similar to those in major
international heart failure trials. Therefore, it is likely that the
performance, safety, and efficacy results of the ANTHEM-
HF study are representative of results that would be expected
in a similar HFrEF population under a similar standard of care
in other parts of the world. Although the overall findings from
ANTHEM-HF and this extension study suggest that open-
loop ART, using left- or right-sided VNS, appears to be feasible
and promising, the next logical step in development is to
confirm these results in an international randomized con-
trolled study.
Conclusions
The results of this 6-month extension of the ANTHEM-
HF study strongly suggest that chronic open-loop ART, using
right- or left-sided VNS, is feasible and well-tolerated in pa-
tients with HFrEF, and is associated with improvements in
objective and subjective efficacy parameters. Improvements
in cardiac function and HF symptoms that were seen after 6
months were maintained after 12 months of ART. Further in-
vestigation of the safety and efficacy of this therapy in
randomized controlled, international clinical studies is
warranted.
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